SG11202103882QA - Nucleic acids for inhibiting expression of lpa in a cell - Google Patents

Nucleic acids for inhibiting expression of lpa in a cell

Info

Publication number
SG11202103882QA
SG11202103882QA SG11202103882QA SG11202103882QA SG11202103882QA SG 11202103882Q A SG11202103882Q A SG 11202103882QA SG 11202103882Q A SG11202103882Q A SG 11202103882QA SG 11202103882Q A SG11202103882Q A SG 11202103882QA SG 11202103882Q A SG11202103882Q A SG 11202103882QA
Authority
SG
Singapore
Prior art keywords
lpa
cell
nucleic acids
inhibiting expression
inhibiting
Prior art date
Application number
SG11202103882QA
Inventor
David Anthony Rider
Lucas Bethge
Christian Frauendorf
Adrien Weingaertner
Judith Hauptmann
Sibylle Dames
Steffen Schubert
Stephan Tenbaum
Original Assignee
Silence Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/081106 external-priority patent/WO2019092283A1/en
Application filed by Silence Therapeutics Gmbh filed Critical Silence Therapeutics Gmbh
Publication of SG11202103882QA publication Critical patent/SG11202103882QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3222'-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • C12N2310/3515Lipophilic moiety, e.g. cholesterol
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/532Closed or circular
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SG11202103882QA 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell SG11202103882QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2018/081106 WO2019092283A1 (en) 2017-11-13 2018-11-13 Nucleic acids for inhibiting expression of lpa in a cell
EP19174466 2019-05-14
PCT/EP2019/081158 WO2020099476A1 (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Publications (1)

Publication Number Publication Date
SG11202103882QA true SG11202103882QA (en) 2021-05-28

Family

ID=66554180

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103882QA SG11202103882QA (en) 2018-11-13 2019-11-13 Nucleic acids for inhibiting expression of lpa in a cell

Country Status (29)

Country Link
US (2) US20220002722A1 (en)
EP (2) EP4219712A3 (en)
JP (1) JP7245328B2 (en)
KR (1) KR102553386B1 (en)
CN (1) CN113227372A (en)
AU (1) AU2019380628A1 (en)
BR (1) BR112021009213A2 (en)
CA (1) CA3119239A1 (en)
CL (1) CL2021001225A1 (en)
CO (1) CO2021007372A2 (en)
CR (1) CR20210301A (en)
DK (1) DK3880818T3 (en)
EA (1) EA202190895A1 (en)
ES (1) ES2932295T3 (en)
FI (1) FI3880818T3 (en)
HR (1) HRP20221358T1 (en)
HU (1) HUE060703T2 (en)
IL (1) IL283159A (en)
LT (1) LT3880818T (en)
MA (1) MA58208B1 (en)
MX (1) MX2021005590A (en)
PE (1) PE20211282A1 (en)
PH (1) PH12021550801A1 (en)
PL (1) PL3880818T3 (en)
PT (1) PT3880818T (en)
RS (1) RS63778B1 (en)
SG (1) SG11202103882QA (en)
SI (1) SI3880818T1 (en)
WO (1) WO2020099476A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3057565A1 (en) * 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
EP4219716A3 (en) 2017-11-13 2024-03-27 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of lpa in a cell
HRP20221358T1 (en) 2018-11-13 2022-12-23 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
EP4229201A1 (en) 2020-10-16 2023-08-23 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
WO2023041508A2 (en) * 2021-09-14 2023-03-23 Argonaute RNA Limited Treatment of cardiovascular disease
WO2023152194A1 (en) 2022-02-09 2023-08-17 Silence Therapeutics Gmbh Therapeutic inhibition of lpa expression
CN114703184A (en) * 2022-03-11 2022-07-05 厦门甘宝利生物医药有限公司 LPA inhibitor and use thereof
WO2024013334A1 (en) * 2022-07-15 2024-01-18 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of agt in a cell
CN115851723B (en) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 RNA inhibitor for inhibiting LPA gene expression and application thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (en) 1992-08-11 1994-03-01 Univ Leiden Triantennary cluster glycosides, their preparation and application.
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US20060160759A1 (en) 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
CN101278059A (en) * 2005-07-28 2008-10-01 肿瘤疗法科学股份有限公司 Method for diagnosing and treating renal cell carcinoma
US20110110886A1 (en) 2008-06-13 2011-05-12 Yale University Small molecule inhibitors of autotaxin and methods of use
US20160272970A1 (en) * 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
JOP20210043A1 (en) * 2015-10-01 2017-06-16 Arrowhead Pharmaceuticals Inc Compositions and Methods for Inhibiting Gene Expression of LPA
EP3228326A1 (en) 2016-04-05 2017-10-11 Silence Therapeutics GmbH Nucleic acid linked to a trivalent glycoconjugate
CA3057565A1 (en) 2017-04-05 2018-10-11 Silence Therapeutics Gmbh Products and compositions
EP3735461A1 (en) * 2017-11-13 2020-11-11 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of aldh2 in a cell
EP4219716A3 (en) * 2017-11-13 2024-03-27 Silence Therapeutics GmbH Nucleic acids for inhibiting expression of lpa in a cell
HRP20221358T1 (en) 2018-11-13 2022-12-23 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell

Also Published As

Publication number Publication date
MA58208B1 (en) 2022-12-30
US20220002722A1 (en) 2022-01-06
ES2932295T3 (en) 2023-01-17
EA202190895A1 (en) 2021-08-10
MX2021005590A (en) 2023-01-24
PH12021550801A1 (en) 2021-10-04
CO2021007372A2 (en) 2021-07-09
HRP20221358T1 (en) 2022-12-23
PL3880818T3 (en) 2023-01-23
WO2020099476A1 (en) 2020-05-22
CR20210301A (en) 2021-09-16
DK3880818T3 (en) 2022-12-05
US11499153B2 (en) 2022-11-15
JP7245328B2 (en) 2023-03-23
EP4219712A3 (en) 2023-11-22
BR112021009213A2 (en) 2021-08-10
SI3880818T1 (en) 2023-01-31
HUE060703T2 (en) 2023-04-28
AU2019380628A1 (en) 2021-05-20
LT3880818T (en) 2022-12-27
EP3880818A1 (en) 2021-09-22
IL283159A (en) 2021-06-30
PT3880818T (en) 2022-12-06
CL2021001225A1 (en) 2021-12-24
RS63778B1 (en) 2022-12-30
FI3880818T3 (en) 2022-12-15
KR20210095878A (en) 2021-08-03
EP4219712A2 (en) 2023-08-02
KR102553386B1 (en) 2023-07-07
JP2022507282A (en) 2022-01-18
CN113227372A (en) 2021-08-06
EP3880818B1 (en) 2022-09-28
US20220170016A1 (en) 2022-06-02
CA3119239A1 (en) 2020-05-22
PE20211282A1 (en) 2021-07-19

Similar Documents

Publication Publication Date Title
IL274503A (en) Nucleic acids for inhibiting expression of lpa in a cell
IL283159A (en) Nucleic acids for inhibiting expression of lpa in a cell
IL290566A (en) Compositions and methods for inhibiting gene expression of lpa
SG11201706636PA (en) Single-cell nucleic acids for high-throughput studies
IL274351A (en) Primary cell gene editing
IL258065B (en) Antisense nucleic acids
GB201611982D0 (en) Cell culture
SG11202102986XA (en) Three-dimensional bioreactors
PL3365107T3 (en) Cell culture
IL274746A (en) Method for culture of cells
PT3710586T (en) Nucleic acids for inhibiting expression of lpa in a cell
IL290750A (en) Nucleic acids for inhibiting expression of c3 in a cell
CA185441S (en) Cell culture insert
PL3287521T3 (en) Cell culture
CA185442S (en) Cell culture insert
GB201716135D0 (en) Improvements in the storage of nucleic acids
PL3367955T3 (en) Tool for handling palatal expanders
GB201621703D0 (en) Method for mapping a nucleic acid sequence
SG10202010002RA (en) Cell culture